Liang Bo, Yin Jun-Jie, Wang Zhong-Liang, Zhan Xin-Rong
Department of Hematology,Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China. E-mail:
Department of Hematology,Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1801-1806. doi: 10.7534/j.issn.1009-2137.2016.06.033.
To study the effect of G protein-coupled receptor kinase 6(GRK6) on proliferation and apoptosis of multiple myeloma(MM) cells and its mechanisms.
The samples were collected from MM patients and healthy people for study in vivo. The plasma cells isolated from multiple myeloma patients, as well as U266 and NCI H929 myeloma cell lines were used for study in vitro. Western blot and quantitative real-time PCR were used to evaluate the protein and mRNA of expression of GRK6 in multiple myeloma, cell proliferation and apoptosis were tested by BrdU and Annexin V-FITC/PI assays.
The protein and mRNA expression of GRK6 in multiple myeloma was higher than those in control group, and the expression level of GRK6 in stage I of MM was higher than that in control group, while the expression level of GRK6 in stage II was higher than that in stage I, but lower than that in stage III (P<0.05). U266 and MM cells showed high-sensitivity to CX-4945, except NCI H929. GRK6 expression level in U266, NCI H929 and MM cells treated with siRNA and CX-4945, significantly decreased as compared with those cells treated by CX-4945 alone. Cell proliferations of U266, NCI H92 and MM groups treated with CX-4945 were (58.25±18.24)%, (64.32±20.03)% and (45.42±25.01)% respectively, moreover, their apoptotic rates were (62.82±53.21)%, (43.25±47.05)% and (85.67±40.32)% respectively.
The expression level of GRK6 in multiple myeloma increases, and GRK6 inhibitor CX-4945 inhibits proliferation and promotes apoptosis of myeloma cells; GRK6 regulates Rac1 and involves in the proliferation and apoptosis pathway of multiple myeloma cells.
研究G蛋白偶联受体激酶6(GRK6)对多发性骨髓瘤(MM)细胞增殖和凋亡的影响及其机制。
收集MM患者和健康人的样本进行体内研究。从多发性骨髓瘤患者中分离的浆细胞以及U266和NCI H929骨髓瘤细胞系用于体外研究。采用蛋白质免疫印迹法(Western blot)和实时定量聚合酶链反应(qRT-PCR)评估GRK6在多发性骨髓瘤中的蛋白和mRNA表达,通过BrdU法和Annexin V-FITC/PI法检测细胞增殖和凋亡情况。
多发性骨髓瘤中GRK6的蛋白和mRNA表达高于对照组,MM I期GRK6表达水平高于对照组,II期高于I期,但低于III期(P<0.05)。U266和MM细胞对CX-4945表现出高敏感性,NCI H929除外。用小干扰RNA(siRNA)和CX-4945处理的U266、NCI H929和MM细胞中GRK6表达水平与单独用CX-4945处理的细胞相比显著降低。用CX-4945处理的U266、NCI H92和MM组细胞增殖率分别为(58.25±18.24)%、(64.32±20.03)%和(45.42±25.01)%,其凋亡率分别为(62.82±53.21)%、(43.25±47.05)%和(85.67±40.32)%。
多发性骨髓瘤中GRK6表达水平升高,GRK6抑制剂CX-4945抑制骨髓瘤细胞增殖并促进其凋亡;GRK6调节Rac1并参与多发性骨髓瘤细胞的增殖和凋亡途径。